Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines
Tae-Han Lee, Yeo-Jin Song, Hyoungyoung Kim, Yoon-Kyoung Sung, Soo-Kyung Cho
J Bone Metab. 2020;27(4):247-259.   Published online 2020 Nov 30     DOI: https://doi.org/10.11005/jbm.2020.27.4.247
Citations to this article as recorded by Crossref logo
Argentine Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Postmenopausal Women and Men Aged 50 Years and Older
Jorge Luis Alberto Morales Torres, Luis Fernando Vidal Neira, Osvaldo Daniel Messina, Willem Lems, Cristiano Zerbini
JCR: Journal of Clinical Rheumatology.2024; 30(2): e74.     CrossRef
Guía de práctica clínica para la prevención, el diagnóstico y el tratamiento de la osteoporosis inducida por glucocorticoides. Asociación Colombiana de Reumatología, 2023
Monique Chalem, Noemi Casas, Aura María Domínguez, Daniel Gerardo Fernández, Andrés González, Edwin Jáuregui, José Fernando Molina, Diana Nathalie Rincón, Carlos Enrique Toro-Gutiérrez, Francisco Juan Vargas Grajales, Susan Martínez, Linda Ibatá
Revista Colombiana de Reumatología.2024; 31(3): 365.     CrossRef
Average daily glucocorticoid dose, number of prescription days, and cumulative dose in the initial 90 days of glucocorticoid therapy are associated with subsequent hip and clinical vertebral fracture risk: a retrospective cohort study using a nationwide h
Masayuki Iki, Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Hironori Imano, Sumito Ogawa
Osteoporosis International.2024; 35(5): 805.     CrossRef
Development and Comparison of Treatment Decision Tools for Glucocorticoid-Induced Osteoporosis
Jia-Feng Chen, Shan-Fu Yu, Wen-Chan Chiu, Chi-Hua Ko, Chung-Yuan Hsu, Han-Ming Lai, Ying-Chou Chen, Yu-Jih Su, Hong-Yo Kang, Tien-Tsai Cheng
Diagnostics.2024; 14(4): 452.     CrossRef
Osteoporosis Etiology, Epidemiology, Diagnosis, Diet, and Treatment: A Narrative Review
Behzad Foroutan
OBM Geriatrics.2024; 08(02): 1.     CrossRef
Clinical practice guideline for the prevention, diagnosis, and treatment of glucocorticoid-induced osteoporosis. Colombian Association of Rheumatology, 2023
Monique Chalem, Noemi Casas, Aura María Domínguez, Daniel Gerardo Fernández, Andrés González, Edwin Jáuregui, José Fernando Molina, Diana Nathalie Rincón, Carlos Enrique Toro-Gutiérrez, Francisco Juan Vargas Grajales, Susan Martínez, Linda Ibatá
Revista Colombiana de Reumatología (English Edition).2024; 31(3): 365.     CrossRef
Ukrainian guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis
N.V. Grygorieva, V.M. Kovalenko, М.О. Коrzh, M.D. Tronko, I.Yu. Golovach, N.V. Dedukh, D.G. Rekalov, S.S. Strafun, S.I. Smiyan, O.A. Golubovska, Ya.O. Dziublyk, N.V. Kharchenko, G.O. Protsenko, O.O. Garmish, V.L. Orlenko, F.V. Klymovytsky, А.S. Musiіenko,
PAIN, JOINTS, SPINE.2024; 14(3): 107.     CrossRef
Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan
Masayuki Iki, Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Kuniyasu Kamiya, Sumito Ogawa
Bone.2023; 166: 116605.     CrossRef
Prevalence of glucocorticoid-induced osteoporosis among rheumatology patients in Africa: a systematic review and meta-analysis
Ihsane Hmamouchi, Farhanah Paruk, Samar Tabra, Kaouther Maatallah, Amal Bouziane, Redouane Abouqal, Yasser El Maidany, Abdellah El Maghraoui, Asgar Ali Kalla
Archives of Osteoporosis.2023;[Epub]     CrossRef
Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis
Juliet E Compston
European Journal of Endocrinology.2023; 188(3): R46.     CrossRef
Medidas básicas orientadas a médicos para prevenir o detectar la osteoporosis inducida por glucocorticoides
María Luisa Peralta-Pedrero, Agles Cruz-Avelar
Alergia, Asma e Inmunología Pediátricas.2023; 32(1-3): 23.     CrossRef
Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study
M. Iki, K. Fujimori, S. Nakatoh, J. Tamaki, S. Ishii, N. Okimoto, K. Kamiya, S. Ogawa
Osteoporosis International.2022; 33(5): 1097.     CrossRef
Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan
Masayuki Iki, Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Kuniyasu Kamiya, Sumito Ogawa
Bone.2022; 160: 116396.     CrossRef
Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club
Michaël R. Laurent, Stefan Goemaere, Charlotte Verroken, Pierre Bergmann, Jean-Jacques Body, Olivier Bruyère, Etienne Cavalier, Serge Rozenberg, Bruno Lapauw, Evelien Gielen
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Comparative effectiveness of bisphosphonate treatments for the prevention of re-fracture in glucocorticoid-induced osteoporosis: protocol for a systematic review and meta-analysis
Hongmin Chu, Bo-Hyoung Jang, GaYoon Kim, Seowoo Bae, Hyeju Lee, Seonghee Nam, Jeonghoon Ahn
BMJ Open.2022; 12(9): e062537.     CrossRef
Real-World Effectiveness of Anti-Osteoporosis Medications for the Prevention of Incident Hip and Vertebral Fractures in Patients on Long-Term Glucocorticoid Therapy: A Nationwide Health Insurance Claims Database Study in Japan
Masayuki Iki, Kenji Fujimori, Shinichi Nakatoh, Junko Tamaki, Shigeyuki Ishii, Nobukazu Okimoto, Kuniyasu Kamiya, Sumito Ogawa
SSRN Electronic Journal .2022;[Epub]     CrossRef
Update on Glucocorticoid Induced Osteoporosis
Soo-Kyung Cho, Yoon-Kyoung Sung
Endocrinology and Metabolism.2021; 36(3): 536.     CrossRef
Understanding of Glucocorticoid Induced Osteoporosis
Chang-Nam Son
Keimyung Medical Journal.2021; 40(2): 69.     CrossRef